Indirect and direct anticoagulants predominantly inhibiting factor Xa
نویسنده
چکیده
6 (2007). 28. Mueck W, Agnelli G, Buller H: Rivaroxaban has predictable pharmacokinetics (PK) and pharmacodynamics (PD) when given once or twice daily for the treatment of acute, proximal deep vein thrombosis (DVT). Blood 110, Abstract 1880 (2007).29. Agnelli G, Gallus A, Goldhaber SZ et al.; for the ODIXa-DVT Study Investigators: Treatment of proximal deep-vein thrombosis with the oral direct factor Xa inhibitor rivaroxaban (BAY 59–7939). The ODIXaDVT Study. Circulation 116, 180–187
منابع مشابه
A novel allosteric pathway of thrombin inhibition: Exosite II mediated potent inhibition of thrombin by chemo-enzymatic, sulfated dehydropolymers of 4-hydroxycinnamic acids.
Thrombin and factor Xa, two important pro-coagulant proteinases, can be regulated through direct and indirect inhibition mechanisms. Recently, we designed sulfated dehydropolymers (DHPs) of 4-hydroxycinnamic acids that displayed interesting anticoagulant properties (Monien, B. H., Henry, B. L., Raghuraman, A., Hindle, M., and Desai, U. R. (2006) Bioorg. Med. Chem. 14, 7988-7998). To better unde...
متن کاملCurrent and future prospects for anticoagulant therapy: inhibitors of factor Xa and factor IIa.
Indirect systemic and direct oral factor Xa and direct oral factor IIa inhibitors with improved pharmacologic profiles compared with heparins and vitamin K antagonists are currently in clinical development. This overview focuses on the indirect antithrombin dependent pentasaccharide derivatives of idraparinux and on the most advanced oral direct inhibitors to factor Xa (rivaroxaban and apixaban...
متن کاملNeue Antikoagulanzien: vom Labor bis zur Klinik
Heparins and vitamin K antagonists have been the cornerstones of anticoagulation therapy for several decades. Although they are very effective at inhibiting the coagulation process, they have several practical limitations. This was a challenge for the development of therapies that will overcome these drawbacks while matching the efficacy of the two classes of anticoagulants. Advances were achie...
متن کاملBleeding Disorders Surgery at High Risk of Bleeding
(VTE) and in some countries for the treatment of acute coronary syndromes. Idraparinux, a subcutaneous, longacting, indirect Factor Xa inhibitor, is in development. Direct inhibition of thrombin or Factor Xa with synthetic, small molecules is an attractive strategy for the development of novel anticoagulants. After the withdrawal of ximelagatran, dabigatran is now the furthest advanced oral, di...
متن کاملReversing factor Xa inhibitors – clinical utility of andexanet alfa
Approximately half of patients started on an oral anticoagulant in the USA now receive one of the newer direct oral anticoagulants (DOACs). Although there is an approved reversal agent for the direct thrombin inhibitor dabigatran, a specific reversal agent for the anti-factor Xa (FXa) DOACs has yet to be licensed. Unlike the strategy to reverse the only oral direct thrombin inhibitor with idaru...
متن کامل